Search

Your search keyword '"Muss, H B"' showing total 360 results
Start Over Author "Muss, H B"
360 results on '"Muss, H B"'

7. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Author

Freedman, Rachel A., Seisler, D. K., Foster, J. C., Sloan, J. A., Lafky, J. M., Kimmick, G. G., Hurria, A., Cohen, H. J., Winer, E. P., Hudis, C. A., Partridge, A. H., Carey, L. A., Jatoi, A., Klepin, H. D., Citron, M., Berry, D. A., Shulman, L. N., Buzdar, A. U., Suman, V. J., and Muss, H. B.

Published
2017
Full Text
View/download PDF

10. Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer

Author

Nyrop, K. A., primary, Damone, E. M., additional, Deal, A. M., additional, Wheeler, S. B., additional, Charlot, M., additional, Reeve, B. B., additional, Basch, E., additional, Shachar, S. S., additional, Carey, L. A., additional, Reeder-Hayes, K. E., additional, Dees, E. C., additional, Jolly, T. A., additional, Kimmick, G. G., additional, Karuturi, M. S., additional, Reinbolt, R. E., additional, Speca, J. C., additional, Wood, W. A., additional, and Muss, H. B., additional

Published
2021
Full Text
View/download PDF

16. Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer

Author

Nyrop, K. A., primary, Deal, A. M., additional, Choi, S. K., additional, Wagoner, C. W., additional, Lee, J. T., additional, Wood, W. A., additional, Anders, C., additional, Carey, L. A., additional, Dees, E. C., additional, Jolly, T. A., additional, Reeder-Hayes, K. E., additional, and Muss, H. B., additional

Published
2018
Full Text
View/download PDF

20. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

Author

Freedman, Rachel A., primary, Seisler, D. K., additional, Foster, J. C., additional, Sloan, J. A., additional, Lafky, J. M., additional, Kimmick, G. G., additional, Hurria, A., additional, Cohen, H. J., additional, Winer, E. P., additional, Hudis, C. A., additional, Partridge, A. H., additional, Carey, L. A., additional, Jatoi, A., additional, Klepin, H. D., additional, Citron, M., additional, Berry, D. A., additional, Shulman, L. N., additional, Buzdar, A. U., additional, Suman, V. J., additional, and Muss, H. B., additional

Published
2016
Full Text
View/download PDF

21. Geriatric Assessment-Identified Deficits in Older Cancer Patients With Normal Performance Status

Author

Messino, M., Pergolotti, M., Jolly, T. A., Moore, S. G., Muss, H. B., Gordon, B.-B. E., Deal, A. M., Wood, W. A., Williams, G. R., Taylor, W. C., Dixon, S. A., Nyrop, K. A., and Alston, S. M.

Abstract

We investigated whether a brief geriatric assessment (GA) would identify important patient deficits that could affect treatment tolerance and care outcomes within a sample of older cancer patients rated as functionally normal (80%–100%) on the Karnofsky performance status (KPS) scale.

Published
2015
Full Text
View/download PDF

23. Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women

Author

Prat, A., Perou, C. M., Muss, H. B., Anders, C. K., Jenkins, E. O., Deal, A. M., and Carey, L. A.

Abstract

Breast cancer (BC) is a disease of aging and the number of older BC patients in the U.S. is rising. Immunohistochemical data show that with increasing age, the incidence of hormone receptor-positive tumors increases, whereas the incidence of triple-negative tumors decreases. Few data exist on the frequency of molecular subtypes in older women. Here, we characterize the incidence and outcomes of BC patients by molecular subtypes and age.

Published
2014
Full Text
View/download PDF

24. Symptom Management in Metastatic Breast Cancer

Author

Muss, H. B., Mayer, D. K., and Irvin, W.

Abstract

Approximately 40,000 women die as a result of breast cancer each year and many more live with advanced disease. When breast cancer recurs, the goals of treatment often shift from one of cure to controlling the disease for as long as possible while palliating symptoms interfering with the patient's functional status and quality of life. This requires ongoing discussions with the patient and family about the goals of care. Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain. The purpose of this paper is to identify and provide an overview of the management of the most common symptoms in patients with breast cancer metastases.

Published
2011
Full Text
View/download PDF

25. Adrenal Hormone and Metabolic Biomarker Responses to 30 min of Intermittent Cycling Exercise in Breast Cancer Survivors.

Author

Evans, E. S., Hackney, A. C., Pebole, M. M., McMurray, R. G., Muss, H. B., Deal, A. M., and Battaglini, C. L.

Subjects
ADRENALINE, BLOOD sugar, BREAST tumors, CANCER patients, CARDIOPULMONARY system, CYCLING, EXERCISE, EXERCISE physiology, EXERCISE tests, FATTY acids, HEART beat, HORMONES, HYDROCORTISONE, LACTATES, LONGITUDINAL method, NORADRENALINE, PROBABILITY theory, PULMONARY gas exchange, RESEARCH, RESEARCH funding, STATISTICS, PSYCHOLOGICAL stress, TUMOR markers, DATA analysis, OXYGEN consumption, ERGOMETRY, DATA analysis software, DESCRIPTIVE statistics, MANN Whitney U Test
Abstract

The aim of this study was to explore the effect of one bout of aerobic exercise on epinephrine, norepinephrine, cortisol, glucose, lactate, and free fatty acid (FFA) responses in breast cancer survivors and healthy controls. 9 female breast cancer survivors and 9 women without a history of cancer completed 30 min of cycle ergometry exercise at 60 % of VO2peak. Blood samples were taken preexercise, immediately post-exercise, and 2 h post-exercise from which plasma concentrations of study variables were measured. Immediately and 2 h post-exercise, increases were observed in epinephrine (control group only) norepinephrine (both groups), lactate (both groups), and FFA (both groups immediately post-exercise; breast cancer survivor group only at 2 h post-exercise) (p < 0.05). Cortisol decreased immediately and 2 h post-exercise in the control group while glucose decreased immediately post-exercise in the breast cancer survivor group (p < 0.05). In conclusion, breast cancer survivors appeared to display attenuated epinephrine, cortisol, and lactate responses while displaying larger magnitude changes in glucose and FFA responses compared to controls. These preliminary findings may have implications for the regulation of metabolism during exercise in breast cancer survivors. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

27. Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort.

Author

Sgroi, D., primary, Carney, E., additional, Richardson, E., additional, Steffel, L., additional, Binns, S. N., additional, Finkelstein, D. M., additional, Shepherd, L. E., additional, Kesty, N. C., additional, Schnabel, C., additional, Erlander, M. G., additional, Ingle, J. N., additional, Porter, P., additional, Paik, S., additional, Muss, H. B., additional, Pritchard, K. I., additional, Tu, D., additional, and Goss, P. E., additional

Published
2011
Full Text
View/download PDF

41. Determinants of Black/White Differences in Colon Cancer Survival

Author

Mayberry, R. M., primary, Coates, R. J., additional, Hill, H. A., additional, Click, L. A., additional, Chen, V. W., additional, Austin, D. F., additional, Redmond, C. K., additional, Fenoglio-Preiser, C. M., additional, Hunter, C. P., additional, Haynes, M. A., additional, Muss, H. B., additional, Wesley, M. N., additional, Greenberg, R. S., additional, and Edwards, B. K., additional

Published
1995
Full Text
View/download PDF

50. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

Author

Christman, K, Muss, H B, Case, L D, and Stanley, V

Subjects
*AGE distribution, *ANALYSIS of variance, *ANTINEOPLASTIC agents, *BREAST tumors, *COMPARATIVE studies, *RESEARCH methodology, *MEDICAL cooperation, *MEDICAL protocols, *METASTASIS, *REGRESSION analysis, *RESEARCH, *RESEARCH funding, *EVALUATION research, *TREATMENT effectiveness
Abstract

Objective: To determine the effect of age on treatment outcome in women with metastatic breast cancer treated with chemotherapy.Design: Case-comparison study of patients with metastic breast cancer treated in five clinical trials of the Piedmont Oncology Association.Setting: University and private practice physicians participating in the Piedmont Oncology Association clinical trials in the southeastern United States.Patients: Seventy patients 70 years of age or older were compared with 60 patients aged 50 through 69 years and 40 patients less than 50 years of age. All patients were ambulatory or capable of self-care, with adequate hematologic, renal, and hepatic function.Interventions: Treatment with multidrug chemotherapy regimens.Main Outcome Measures: Response to treatment, time to disease progression, survival, and toxic effects.Results: Pretreatment characteristics including race, performance status, disease-free interval, prior therapy, sites of metastatic disease, and number and dominant sites of metastases were similar for the three age groups. The response rates for the younger-than-50, 50-through-69, and 70-or-older age groups were 40%, 31%, and 29%, respectively (P = .53). There were no significant differences in time to disease progression or survival for patients in the three age groups. Estimates for time to progression and survival were 9.1 and 17.9 months, 6.2 and 12.8 months, and 7.2 and 14.2 months, respectively. Toxic effects, dose delivery, and dose delays were also similar for all three age groups.Conclusions: Women 70 years of age or older who were enrolled in these trials were similar to their younger counterparts in response rates, time to disease progression, survival, and toxic effects. Women in this age group should not be excluded, based on age alone, from clinical trials involving chemotherapy for advanced breast cancer. [ABSTRACT FROM AUTHOR]

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results